What is Odyssey Therapeutics, Inc. stock ticker?

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Odyssey Therapeutics, Inc. stocks are traded under the ticker ODTX.

Is Odyssey Therapeutics, Inc. stock price growing?

ODTX stock has fallen by −3.13% compared to the previous week, the month change is a 2.72% rise, over the last year Odyssey Therapeutics, Inc. has showed a 2.72% increase.

What are Odyssey Therapeutics, Inc. stock highest and lowest prices ever?

ODTX reached its all-time high on May 22, 2026 with the price of 18.43 USD, and its all-time low was 16.41 USD and was reached on May 11, 2026. View more price dynamics on ODTX chart. See other stocks reaching their highest and lowest prices.

How volatile is ODTX stock?

ODTX stock is 6.85% volatile and has beta coefficient of −7.96. Track Odyssey Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Odyssey Therapeutics, Inc. there?

Does Odyssey Therapeutics, Inc. release reports?

Yes, you can track Odyssey Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.

Does Odyssey Therapeutics, Inc. pay dividends?

No, ODTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.

How to buy Odyssey Therapeutics, Inc. stocks?

Like other stocks, ODTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Odyssey Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.

Odyssey Therapeutics, Inc. IPO Details, GMP, Subscription & Allotment

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

eBooks

Company

Home About Us Privacy Policy Terms of Service

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

Want to stay updated?Subscribe to our newsletter

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

eBooks

Company

Home About Us Privacy Policy Terms of Service

About IPO Scanner

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Want to stay updated?Subscribe to our newsletter

About

Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.

The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.

The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Odyssey Therapeutics, Inc. Overview

Ticker, listing venue and issuer profile

TickerODTX

ExchangeNASDAQ

Statuslisted

SectorHealthcare

IndustryBiotechnology

CurrencyUSD

CIK Code1882782

CUSIP67613T104

ISINUS67613T1043

Offer & Key Dates

Pricing terms and IPO milestones

Price Range$16.00 - $18.00

Offer Price--

Listing Price$20.00

Current Price$17.61

Shares Offered13.24M

Shares Outstanding47.17M

Offer Size$225.08M

Market Cap$802.43M

Filing Date--

Priced DateMay 08, 2026

Listed DateMay 08, 2026

Live Market Snapshot

Real-time price; headline % change is vs first trade (listing price)

$17.01-11.95% All time

USD · NASDAQ:NASDAQ:ODTX

Open$17.95

High$18.02

Low$16.86

Volume165,302

52W High$18.43

52W Low$16.41

Market Cap$802.43M

Enterprise Value--

Valuation & Multiples

Key valuation ratios and metrics

P / E--

P / Book--

P / Sales--

EV / EBITDA--

EPS--

Revenue / Share (TTM)--

Revenue$2.98M

Net Income-$148.65M

Financial Health

Balance sheet strength and liquidity

Total Debt$27.11M

Total Assets$274.89M

Cash$41.69M

Free Cash Flow--

Current Ratio7.2

Quick Ratio7.2

Debt / Equity0.13

CapEx--

Profitability & Returns

Margins and return on capital

Gross Margin--

Operating Margin--

Net Margin--

Return on Equity-85.52%

Return on Assets-61.83%

ROIC-75.08%

EBITDA--

Gross Profit-$1.94M

Risk Metrics

Volatility versus the market

Beta-7.96

3Y Beta--

5Y Beta--

Financial Highlights

Historical financial performance

Historical Data

Market history and supplemental quote data

Date	Open	High	Low	Close	Adj. Close	Change	Volume
2026-05-29	$17.95	$18.02	$16.86	$17.01	$17.01	-0.94	165,300
2026-05-28	$17.35	$18.31	$16.73	$17.92	$17.92	+0.57	309,200
2026-05-27	$17.97	$18.30	$17.04	$17.19	$17.19	-0.78	405,100
2026-05-26	$17.24	$18.30	$16.98	$17.56	$17.56	+0.32	400,100
2026-05-22	$17.56	$18.43	$16.50	$17.50	$17.50	-0.06	323,600
2026-05-21	$17.00	$18.24	$16.75	$17.74	$17.74	+0.74	408,100
2026-05-20	$16.93	$17.50	$16.78	$16.97	$16.97	+0.04	389,000
2026-05-19	$17.39	$17.65	$16.75	$16.94	$16.94	-0.45	376,500
2026-05-18	$17.55	$17.71	$17.00	$17.39	$17.39	-0.16	371,800
2026-05-15	$17.15	$17.86	$17.00	$17.62	$17.62	+0.47	405,100
2026-05-14	$17.92	$17.94	$17.08	$17.32	$17.32	-0.60	356,700
2026-05-13	$18.06	$18.06	$17.40	$17.94	$17.94	-0.12	316,300
2026-05-12	$17.61	$18.06	$17.27	$17.90	$17.90	+0.29	171,200
2026-05-11	$16.56	$17.72	$16.41	$17.45	$17.45	+0.89	427,000
2026-05-08	$20.00	$20.30	$15.35	$16.42	$16.42	-3.58	3,170,900

SEC Filings

Official documents from SEC EDGAR

Form	Filing Date	Document
SCHEDULE 13G	May 18, 2026	Filing
SCHEDULE 13D	May 18, 2026	Filing
SCHEDULE 13D	May 18, 2026	Filing
SCHEDULE 13D	May 15, 2026	Filing
SCHEDULE 13D	May 15, 2026	Filing
8-K	May 11, 2026	Current Report
S-8	May 11, 2026	Securities to be offered to employees in employee benefit plans
424B4	May 8, 2026	Prospectus
EFFECT	May 7, 2026	Notice of Effectiveness
S-1MEF	May 7, 2026	Registration adding securities to prior Form S-1 registration

Company Info

Contact and headquarters details

Websitehttps://odysseytx.com

HeadquartersUnited States

Founded2021

Employees100

Phone617 865 9628

Address51 Sleeper Street, Suite 800Boston, Massachusetts 02210United States

Leadership

Key executives and officers

Gary D. Glick, Ph.D.

President, Chief Executive Officer and Director

Julie Clauss

Chief Operating Officer

Jason Haas

Chief Financial Officer

William Roush, Ph.D.

Executive Vice President, Head of Small Molecule Research

Kira M. Schwartz

Executive Vice President, General Counsel and Secretary

Stephen Soisson, Ph.D.

Executive Vice President, Protein Therapeutics and Structural Biology

Collin Todd

Senior Vice President, Strategy and Business Development

Jeffrey M. Leiden, M.D., Ph.D.

Chair and Director

Charles Baum, M.D., Ph.D.

Director

Jill Carroll